TABLE 1.
Population pharmacokinetic simulations with tedizolid and linezolid
| Parametera | Value |
|
|---|---|---|
| Tedizolidb | Linezolidc | |
| Mean (SE) MPS IC50 (μM) | 0.31 (0.02) | 6.4 (1.2) |
| Time below MPS IC50 (h) | ||
| Mean (SD) | 7.62 (5.49) | 3.17 (5.29) |
| Median | 7.94 | 0 |
| 25th–75th percentiles | 2.48–11.92 | 0–4.93 |
| % of patients with all free drug concentrations above the IC50 | 16 | 62 |
a
IC50, 50% inhibitory concentration; MPS, mitochondrial protein synthesis.
b
Administered as 200 mg once daily; protein binding of 80% was assumed.
c
Administered as 600 mg twice daily; protein binding of 31% was assumed.